Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: Implications in graft-versus-host disease and antitumor immunity

Journal of Immunology

Volumn 179, Issue 11, 2007, Pages 7593-7604

  Pallandre, Jean René ^a   Brillard, Emilie ^a   Créhange, Gilles ^b   Radlovic, Amandine ^a   Remy Martin, Jean Paul ^a   Saas, Philippe ^a   Rohrlich, Pierre Simon ^a   Pivot, Xavier ^a,b   Ling, Xiang ^c   Tiberghien, Pierre ^a   Borg, Christophe ^a,b,d  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^b UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^c UNIVERSITY OF TEXAS   (United States)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; RNA; SMALL INTERFERING RNA; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1; CD3 ANTIGEN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; MESSENGER RNA; STAT3 PROTEIN, MOUSE; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; C57BL 6 MOUSE; CD25+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; FLOW CYTOMETRY; GENE TRANSFER; GENETIC TRANSFECTION; GRAFT VERSUS HOST REACTION; IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; MOUSE; NONHUMAN; PHENOTYPE; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PURIFICATION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; RNA SYNTHESIS; THYMOCYTE; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CANCER TRANSPLANTATION; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MALE; METABOLISM; METHODOLOGY; NEOPLASM; PHOSPHORYLATION; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSPLANTATION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD28; ANTIGENS, CD3; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GRAFT VS HOST DISEASE; IMMUNOTHERAPY, ADOPTIVE; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEOPLASMS; PHENOTYPE; PHOSPHORYLATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, REGULATORY;

EID: 38849093957     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.11.7593     Document Type: Article

References (64)

1. + T cells: evidence from a lymphopenic T cell model. Immunity 17: 425-436.
2. Walker, L. S., and A. K. Abbas. 2002. The enemy within: keeping self reactive T cells at bay in the periphery. Nat. Rev. Immunol. 2: 11-19.
3. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22: 531-562.
4. Sakaguchi, S. 2000. Regulatory T cells: key controllers of immunologic selftolerance. Cell 101: 455-458.
5. + regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192: 303-310.
6. + regulatory cells that control intestinal inflammation. J. Exp. Med. 192: 295-302.
7. + regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol. 3: 135-142.
8. Hori, S., T. Nomura, and S. Sakaguchi. 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057-1061.
9. + regulatory T cells. Nat. Immunol. 4: 330-336.
10. + T regulatory cells. Nat. Immunol. 4: 337-342.
11. Apostolou, I., A. Sarukhan, L. Klein, and H. Boehmer. 2001. Origin of regulatory T cells with known specificity for antigen. Nat. Immunol. 3: 756-763.
12. + regulatory T cells by oral antigen administration. J. Immunol. 167: 4245-4253.
13. + regulatory T cells by TGF-β induction of transcription factor Foxp3. J. Exp. Med. 198: 1875-1886.
14. + regulatory T cells in vivo requires B7 costimulation, but not the thymus. J. Exp. Med. 201: 127-137.
15. + regulatory T cells. Eur. J. Immunol. 32: 1621-1630.
16. +. J. Immunol. 172: 6123-6128.
17. - T cells. J. Clin. Invest. 112: 1437-1443.
18. + immunoregulatory T cells that control autoimmune diabetes. Immunity 12: 431-440.
19. + regulatory T cells. J. Immunol. 171: 3348-3352.
20. Tai, X., M. Cowan, L. Feigenbaum, and A. Singer. 2005. CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. Nat. Immunol. 6: 152-162.
21. + regulatory T cells suppress lethal acute graft-versushost disease after allogeneic bone marrow transplantation. J. Exp. Med. 196: 389-399.
22. + immune regulatory cells inhibits graft-versus-host disease lethality. Blood 99: 3493-3499.
23. + immunoregulatory T cells: new therapeutics for graft-versus-host disease. J. Exp. Med. 196: 401-406.
24. Liyanage, U. K., T. T. Moore, H. G. Joo, Y. Tanaka, V. Herrmann, G. Doherty, J. A. Drebin, S. M. Strasberg, T. J. Eberlein, P. S. Goedegebuure, and D. C. Linehan. 2002. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169: 2756-2761.
25. Wolf, D., A. M. Wolf, H. Rumpold, H. Fiegl, A. G. Zeimet, E. Muller-Holzner, M. Deibl. M, G. Gast, E. Gunsilius, and C. Marth. 2005. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin. Cancer Res. 11: 8326-8331.
26. + regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 98: 1089-1099.
27. + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61: 4766-4772.
28. Curiel, T. J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10: 942-949.
29. + regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 34: 336-344.
30. + regulatory T cell proliferation. J. Exp. Med. 202: 919-929.
31. Garcia, R., C. L. Yu, A. Hudnall, R. Catlett, K. L. Nelson, T. Smithgall, D. J. Fujita, S. P. Ethier, and R. Jove. 1997. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ. 8: 1267-1276.
32. Kotenko, S. V., L. S. Izotova, O. V. Mirochnitchenko, C. Lee, and S. Pestka. 1999. The intracellular domain of interferon-α receptor 2c (IFN-αR2c) chain is responsible for Stat activation. Proc. Natl. Acad. Sci. USA 96: 5007-5012.
33. Rani, M. R., D. W. Leaman, Y. Han, S. Leung, E. Croze, E. N. Fish, A. Wolfman, and R. M. Ransohoff. 1999. Catalytically active TYK2 is essential for interferon-β-mediated phosphorylation of STAT3 and interferon-α receptor-1 (IFNAR-1) but not for activation of phosphoinositol 3-kinase. J. Biol. Chem. 274: 32507-32511.
34. Bromberg, J. F., M. H. Wrzeszczynska, G. Devgan, Y. Zhao, R. G. Pestell, C. Albanese, and J. E. Darnell Jr.. 1999. Stat3 as an oncogene. Cell 98: 295-303.
35. Wang, T., G. Niu, M. Kortylewski, T. Wang, G. Niu, L. Burdelya, K. Shain, S. Zhang, R. Bhattacharya, D. Gabrilovich, et al. 2004. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 10: 48-54.
36. Kortylewski, M., M. Kujawski, T. Wang, S. Wei, S. Zhang, S. Pilon-Thomas, G. Niu, H. Kay, J. Mule, W. G. Kerr, et al. 2005. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 11: 1314-1321.
37. Kinjyi, I., H. Inoue, S. Hamano, S. Fukuyama, T. Yoshimura, K. Koga, H. Takaki, K. Himeno, G. Takaesu, T. Kobayashi, and A. Yoshimura. 2006. Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor β 1. J. Exp. Med. 203: 1021-1031.
38. Bromberg, J. F., M. H. Wrzeszczynska, G. Devgan, Y. Zhao, R. G. Pestell, C. Albanese and J. E. Darnell. 1999. Stat3 as an oncogene. Cell 98: 295-303.
39. Cooke, K. R., L. Kobzik, T. R. Martin, J. Brewer, J. Delmonte Jr., J. M. Crawford, and J. L. Ferrara. 1996. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation, I: the roles of minor H antigens and endotoxin. Blood 88: 3230-3239.
40. Kleinclauss, F., S. Perruche, E. Masson, M. de Carvalho Bittencourt, S. Biichle, J. P. Remy-Martin, C. Ferrand, M. Martin, H. Bittard, J. M. Chalopin, et al. 2006. Intravenous apoptotic spleen cell infusion induces a TGF-β-dependent regulatory T-cell expansion. Cell Death Differ. 13: 41-52.
41. Takeda, K., B. E. Clausen, T. Kaisho, T. Tsujimura, N. Terada, I. Forster, and S. Akira. 1999. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10: 39-49.
42. Alonzi, T., I. P. Newton, P. J. Bryce, E. Di. Carlo, G. Lattanzio, M. Tripodi, P. Musiani, and V. Poli. 2004. Induced somatic inactivation of STAT3 in mice triggers the development of a fulminant form of enterocolitis. Cytokine 26: 45-56.
43. Welte, T., S. S. Zhang, T. Wang, Z. Zhang, D. G. Hesslein, Z. Yin, A. Kano, Y. Iwamoto, E. Li, J. E. Craft, et al. 2003. STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proc. Natl. Acad. Sci. USA 100: 1879-1884.
44. Holdorf, A. D., K. H. Lee, W. R. Burack, P. M. Allen, and A. S. Shaw. 2002. Regulation of Lck activity by CD4 and CD28 in the immunological synapse. Nat. Immunol. 3: 259-264.
45. Golubovskaya, V. M., S. Gross, A. S. Kaur, R. I. Wilson, L. H. Xu, X. H. Yang, and W. G. Cancer. 2003. Simultaneous inhibition of focal adhesion kinase and SRC enhances detachment and apoptosis in colon cancer cell lines. Mol. Cancer Res. 1: 755-764.
46. Cheng, F., H. W. Wang, A. Cuenca, M. Huang, T. Ghansah, J. Brayer, W. G. Kerr, K. Takeda, S. Akira, S. P. Schoenberger, et al. 2003. A critical role for Stat3 signaling in immune tolerance. Immunity 19: 425-436.
47. Su, L., and M. David. 2000. Distinct mechanisms of STAT phosphorylation via the interferon-α/β receptor: selective inhibition of STAT3 and STAT5 by piceatannol. J. Biol. Chem. 275: 12661-12666.
48. Turkson, J., D. Ryan, J. S. Kim, Y. Zhang, Z. Chen, E. Haura, A. Laudano, S. Sebti, A. D. Hamilton, and R. Jove. 2001. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J. Biol. Chem. 276: 45443-45455.
49. Song, H., R. Wang, S. Wang, and J. Lin. 2005. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc. Natl. Acad. Sci. USA 102: 4700-4705.
50. + T cells. J. Exp. Med. 185: 461-469.
51. Powell, B. R., N. R. Buist, and P. Stenzel. 1982. An X-linked syndrome of diarrhea, polyendocrinopathy, and fatal infection in infancy. J. Pediatr. 100: 731-737.
52. Satake, N., M. Nakanishi, M. Okano, K. Tomizawa, A. Ishizaka, K. Kojima, M. Onodera, T. Ariga, A. Satake, and Y. Sakiyama. 1993. A Japanese family of X-linked auto-immune enteropathy with haemolytic anaemia and polyendocrinopathy. Eur. J. Pediatr. 152: 313-315.
53. Bennett, C. L., J. Christie, F. Ramsdell, M. E. Brunkow, P. J. Ferguson, L. Whitesell, T. E. Kelly, F. T. Saulsbury, P. F. Chance, and H. D. Ochs. 2001. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27: 20-21.
54. Gavin, M. A., T. R. Torgerson, E. Houston, P. DeRoos, W. Y. Ho, A. Stray-Pedersen, E. L. Ocheltree, P. D. Greenberg, H. D. Ochs, and A. Y. Rudensky. 2006. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc. Natl. Acad. Sci. USA 103: 6659-6664.
55. + Tregs. J. Clin. Invest. 115: 3276-3284.
56. + regulatory T cells in cancer patients. Blood 107: 2409-2414.
57. + regulatory T cells through a STAT dependent mechanism and induces the expansion of these cells in vivo. Blood 108: 1571-1579.
58. Fontenot, J. D., J. P. Rasmussen, M. A. Gavin, and A. Y. Rudensky. 2005. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. 6: 1142-1151.
59. + T helper cells. J. Exp. Med. 196: 255-260.
60. Kasprzycka, M., M. Marzec, X. Liu, Q. Zhang, and M. A. Wasik. 2006. Nucleoplasmin/ anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. Proc. Natl. Acad. Sci. USA 103: 9964-9969.
61. Anderson, P. O., B. A. Manzo, A. Sundstedt, S. Minaee, A. Symonds, S. Khalid, M. E. Rodriguez-Cabezas, K. Nicolson, S. Li, D. C. Wraith, and P. Wang. 2006. Persistent antigenic stimulation alters the transcription program in T cells, resultaing in antigen specific tolerence. Eur. J. Immunol. 36: 1374-1385.
62. Wan, Y. Y., and R. A. Flavell. 2007. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature 445: 766-770.
63. Ling, X., And R. B. Arlinghaus. 2005. Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. Cancer Res. 65: 2532-2536.
64. Wakkach, A., N. Fournier, V. Brun, J. P. Breittmayer, F. Cottrez, and H. Groux. 2003. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 18: 605-617.